The chimeric gene, AML1/ETO (MTG8), generated in t(8;21) acute myeloid leukemia enhances the expression of Bcl-2. To evaluate whether this enhancement is the primary role of AML1/ETO in leukemogenesis, eects of over-expression of Bcl-2 in the murine myeloid precursor cell line, 32Dcl3, were examined. When 32Dcl3 cells expressing exogenous Bcl-2 were induced to dierentiate, the onset of morphological dierentiation was delayed. However, even the cells expressing very high levels of exogenous Bcl-2 eventually underwent dierentiation without a signi®cant decrease in the synthesis of Bcl-2. On the contrary, 32Dcl3 cells stably expressing AML1/ETO were completely resistant to dierentiation and continued to grow in the presence of G-CSF. These results are consistent with the interpretation that stimulation of Bcl-2 expression is not the primary target of AML1/ETO.
Introduction
The AML1 gene was originally identi®ed at the breakpoint of t(8;21) acute myeloid leukemia (Miyoshi et al., 1991) and is now known to be the most frequent target of chromosome translocations associated with human leukemia including t(3;21) and t(12;21) (Look, 1997) . AML1 has an essential role in inducing de®nitive hematopoiesis and plays pivotal roles in regulating cell type speci®c genes in various hematopoietic cells (Okuda et al., 1996; Wang et al., 1996; Sasaki et al., 1996; Okada et al., 1998) . AML1, also called polyomavirus enhancer binding protein 2aB gene (PEBP2aB) or core binding factor A2 gene (CBFA2), is one of three mammalian Runt-domainencoding genes and its product is the a subunit of a heterodimeric transcription factor PEBP2/CBF (reviewed by Speck et al., 1995; Ito, 1996; Ito et al., 1997) .
In t(8;21) AML, the N-terminal region of AML1 comprising the Runt domain, a highly conserved region required for DNA binding and heterodimerization with the b subunit, is fused to ETO(MTG8), generating the AML1/ETO(MTG8) fusion gene product (Erickson et al., 1992; Miyoshi et al., 1993) . In t(3;21), several fusion products are formed, the major one being AML1/EVI-1 in which the same Nterminal region of AML1 present in AML1/ETO is fused to EVI-1 (Nucifora et al., 1993 (Nucifora et al., , 1994 (Nucifora et al., , 1995 Mitani et al., 1994) . In the case of t(12;21), the chimeric protein produced, termed TEL/AML1, contains the N-terminal half of a member of the Ets family, TEL, fused to the entire AML1 on the Cterminal side (Golub et al., 1995; Romana et al., 1995) . All of these chimeric proteins retain the Runt domain of AML1, suggesting their potential ability to bind to DNA and interact with the b subunit. In addition, the gene encoding the b subunit of PEBP2 is involved in the chromosome anomaly associated with inv(16) acute myeloid leukemia (Liu et al., 1993) . In this case, the chimeric gene, b/MYH11 encoding the chimeric protein, b/SMMHC, is produced. b/SMMHC contains the C-terminal coiled-coil region of SMMHC (smooth muscle myosine heavy chain) fused to the C-terminal region of the b subunit protein. This chimeric protein forms a dimer with AML1 more readily than the normal b subunit (Lu et al., 1995; Kanno et al., 1998) . We and others have shown that these chimeric genes strongly inhibit the activity of a variety of promoters through the PEBP2 sites, including T cell receptor b enhancer/promoter Tanaka et al., 1995; Hiebert et al., 1996) , GM-CSF promoter (Frank et al., 1995) , IL-3 promoter (Uchida et al., 1997) , M-CSF receptor promoter (Fears et al., 1997; Kanno et al., 1998) and Moloney murine leukemia virus enhancer (Liu et al., 1994) .
Recently, it has been reported that eight out of 160 patients with leukemia have point mutations in AML1. These mutations are all clustered in the Runt domain. Three heterozygous mutants of AML1 show neither DNA binding nor transactivation. These loss-offunction mutations may be related to predisposition to, or the progression of leukemia. In two other cases, biallelic nonsense mutants were found which encode AML1 truncated within the Runt domain. In these two cases, essentially all of the AML1 function was destroyed (Osato et al., 1999) . These results coupled with the observations mentioned above that chimeric genes involving AML1 or the b subunit gene strongly inhibit transcription lead to a hypothesis that a loss of AML1 function at appropriate stage of myeloid cell development plays a role in leukemogenesis.
In contradiction of the above hypothesis, Bcl-2 (Klampfer et al., 1996) and macrophage colony stimulation factor (M-CSF) receptor promoters (Rhoades et al., 1996) are upregulated by AML1/ ETO. A PEBP2 binding site has been identi®ed in the 5' untranslated region of the Bcl-2 gene, and AML1/ ETO, but not AML1 or ETO, activates transcription of Bcl-2 (Klampfer et al., 1996) . The Bcl-2 gene was ®rst identi®ed at the breakpoint of t(14;18) follicular lymphoma (Bakhshi et al., 1985; Cleary et al., 1985; Tsujimoto et al., 1985) . Numerous studies have demonstrated the ability of Bcl-2 to protect cells of lymphoid, myeloid and neuronal lineages from apoptosis (Reed, 1994) . Genes that regulate cell death are potentially important targets for leukemogenic chimeric transcription factors.
AML1/ETO(MTG8) blocks dierentiation of Kasumi-1 cells harboring t(8;21) obtained from an acute myeloid leukemia patient (Asou et al., 1991) . A similar dierentiation block can be observed in the murine myeloid progenitor cell line, 32Dcl3 (Valtieri et al., 1987) or L-G (Kinashi et al., 1991) , which requires interleukin 3 (IL-3) for growth and undergoes granulocytic dierentiation when IL-3 is replaced by G-CSF. Stable expression of AML1/ETO or AML1/ EVI-1 prevent G-CSF-induced granulocytic differentiation in 32Dcl3 (Ahn et al., 1998; Tanaka et al., 1995) or L-G cells (Kitabayashi et al., 1998) .
Using this cell system, we evaluated whether upregulation of Bcl-2 by AML1/ETO is the primary role of the chimeric gene in gross changes of growth and dierentiation properties of 32Dcl3 cells.
Results

Elevated levels of Bcl-2 in cell lines carrying AML1/ ETO(MTG8) and b/SMMHC
Kasumi-1 and SKNO-1 cells derived from t(8;21) acute myeloid leukemia patients and expressing AML1/ETO have elevated levels of Bcl-2 protein compared with cell lines obtained from acute myeloid leukemia patients not harboring AML1/ETO (Klampfer et al., 1996) . We con®rmed that the Kasumi-1 and SKNO-1 cell lines synthesized elevated levels of Bcl-2 proteins compared to the myelomonocytic leukemia cell line, U937 and promyelocytic leukemia cell line, HL-60 (Figure 1) . ME-1 cells harboring inv(16) synthesize the chimeric protein, b/SMMHC. Like AML1/ETO, b/SMMHC deregulates the expression of genes which are the target of AML1 (Liu et al., 1994; Kanno et al., 1998) . As shown in Figure 1 , ME-1 cells also express elevated levels of Bcl-2 compared with U937 and K562 cells.
Rapid decrease of Bcl-2 levels in 32Dcl3 cells undergoing granulocytic dierentiation
The murine myeloid progenitor cell line, 32Dcl3, requires IL-3 for growth. 32Dcl3 cells continue to grow for about 6 days after replacement of IL-3 with G-CSF, then undergo gross morphological differentiation on, or around day 7 and thereafter gradually lose viability under the conditions used ( Figure 2A) .
In 32Dcl3 cells, Bcl-2 protein was expressed in the presence of IL-3 but the level of expression decreased rapidly after replacing IL-3 with G-CSF ( Figure 2B ). On day 4 in the G-CSF containing medium, Bcl-2 protein became undetectable. At this time point, cells still did not show any morphological changes.
We and others have shown that AML1/ETO blocks dierentiation of 32Dcl3 cells induced by G-CSF (Ahn et al., 1998; Kitabayashi et al., 1998) . We con®rmed the observation: 32Dcl3 cells stably expressing AML1/ ETO continue to grow up to 10 days even after IL-3 was replaced with G-CSF ( Figure 2A ). Under such conditions, the level of the Bcl-2 expression was maintained at the level observed in the presence of IL-3 ( Figure 2C ).
Expression of exogenous Bcl-2 increases survival of 32Dcl3 cells
The rapid decrease of Bcl-2 levels during granulocytic dierentiation and the unaltered expression of Bcl-2 in the cells stably expressing AML1/ETO even in the presence of G-CSF raised the possibility that a decrease of Bcl-2 levels is a prerequisite for differentiation. To examine this possibility, 32Dcl3 cells expressing exogenous murine Bcl-2 from a constitutively active promoter (32D-Bcl2) were obtained and the in¯uence of exogenous Bcl-2 on the cells was tested.
Over-expression of Bcl-2 has been shown to delay apoptosis in a number of cytokine-dependent cell lines upon cytokine deprivation (Nunez et al., 1990; Bay et al., 1993; Rodel et al., 1996) and to mediate the survival signal provided by cytokines (Lin et al., 1996) . Therefore, to examine whether expression of exogenous Bcl-2 can prevent cell death, 32D-Bcl2 was tested for survival after removal of IL-3. Parental 32Dcl3 cells rapidly lost viability in medium containing serum lacking IL-3 or G-CSF and within 48 h of culture in the absence of IL-3 most of the cells were non-viable. These observations are consistent with previous reports (Nunez et al., 1990; Bay et al., 1993; Rodel et al., 1996) . On the contrary, the cell number of 32D-Bcl2 doubled after the removal of IL-3 before losing viability, and about 50% of the cells were still alive 4.5 days after the removal of cytokine. The cells that had received only the vector, 32D-neo, behaved like parental cells (Figure 3 ). The level of expression of Bcl-2 in 32D-Bcl2 was about 7.5 times as much as that of the parental cells or 32D-neo as revealed by immunoblot analysis (see Figure 4A) .
Interestingly, 32Dcl3 cells stably expressing AML1/ ETO, 32D-AML1/ETO did not show a signi®cant increase in survival in the absence of IL-3, despite the fact that these cells grew continuously in the presence of G-CSF under conditions that induced parental cell dierentiation (Figure 2A ).
Over-expression of Bcl-2 delays dierentiation of 32Dcl3
Next, the in¯uence of over-expression of Bcl-2 on dierentiation was examined. When cultured in IL-3 containing medium, 32D-Bcl2 maintained the morphology of myeloid precursor cells like parental or 32D-neo cells. Also the growth rate of these cells was indistinguishable (data not shown).
When IL-3 was replaced with G-CSF, 32D-neo cells stopped growing and underwent dierentiation around day 8 like parental cells (Figures 2A and 4B) . On the contrary, 32D-Bcl2 continued to multiply beyond day 8 up until day 12 without showing any sign of morphological dierentiation. Around day 12, however, 32D-Bcl2 stopped growing and morphological dierentiation became evident. In other words, exogenous Bcl-2 delayed but did not completely block granulocytic dierentiation. In addition, the rate of decrease of the viable cell number was signi®cantly lower than that of 32D-neo, consistent with the increase in the survival rate of these cells described above (Figure 3) . It is important to note that the high levels of Bcl-2 expression from the exogenously introduced constitutive promoter were maintained in 32D-Bcl2 throughout the period examined, even after morphological dierentiation became evident and viability of the cells declined ( Figure 4C ). This is in contrast to 32D-neo in which Bcl-2 was no longer detectable on day 6 ( Figure 4C) .
Since the results shown in Figure 4A , B and C were obtained with a population of cells expressing Bcl-2 at dierent levels, we examined the eect of exogenous Bcl-2 more precisely using individual cell clones obtained from these cell cultures.
Levels of expression of Bcl-2 in independent clones varied widely as revealed by Western blotting ( Figure  4D ). We chose clone 20 (cl-20), clone 6 (cl-6) and clone 9 (cl-9) as low-, moderate-and high-level expressors of Bcl-2 respectively. Relative levels of expression of Bcl-2 in cl-20, cl-6, cl-9 and the parent cells were 1.6, 7.4, 9.5 and 1.0, respectively.
The growth curve and the timing of morphological dierentiation of cl-20 in G-CSF was indistinguishable from those of the parental cells. cl-6 and cl-9, on the other hand, stopped growing on day 9 and day 12, respectively ( Figure 4E ) and underwent morphological changes ( Figure 5) . The results indicated a correlation between the levels of Bcl-2 expression, the timing of dierentiation and the slope of the decrease of viable cell number after dierentiation. In other words, the higher the level of Bcl-2 expressed, the slower the timing of dierentiation and the less steep the decline in viable cell number. Taken together, the results indicated that over-expression of Bcl-2 reduces the cell death that accompanies granulocytic dierentiation 
Discussion
Although Bcl-2 was expressed at elevated levels in leukemic cell lines synthesizing AML1/ETO or b/ SMMHC, over-expression of exogenous Bcl-2, even at very high levels, did not completely block G-CSF induction of the granulocytic dierentiation of the murine myeloid progenitor cell line, 32Dcl3. This is in contrast to AML1/ETO which was able to completely block the dierentiation of these cells. These results suggest that the major target of AML1/ETO is unlikely to be upregulation of Bcl-2, although upregulation of Bcl-2 would contribute to leukemogenesis by increasing resistance to cell death.
Earlier studies have shown that overexpression of Bcl-2 has little or no eect on cell dierentiation or proliferation (Vaux et al., 1988; Nunez et al., 1990) . Despite these reports, expression of Bcl-2 was shown to be stimulated by AML1/ETO, implying that stimulation of Bcl-2 expression is one factor in the leukemogenic potential of this chimeric gene (Klampfer et al., 1996) . Furthermore, Lin et al. (1996) also reported the possibility of inhibition of dierentiation of 32Dcl3 cells by Bcl-2. For the induction of dierentiation, however, they removed IL-3. Under such conditions, 32Dcl3 cells died rapidly and only a small portion of the cells (5 ± 20%) showed morphological changes. In the present study, after replacement of IL-3 with G-CSF, cells continued to grow for several days and virtually all of the cells underwent gross morphological changes. Thus, our experimental design is likely to re¯ect more closely physiological conditions and provide a better basis for the analysis of the eect of Bcl-2.
Although up-regulation of Bcl-2 in cell lines carrying t(8;21) was observed in the present study, the question still remains as to whether primary leukemic cells with t(8;21) actually express higher levels of Bcl-2 in vivo. Recently, Banker et al. (1998) reported that the t(8;21) translocation was not consistently associated with high Bcl-2 expression in de novo. Earlier, Bcl-2 expression was reported to be negatively regulated by p53 (Miyashita et al., 1994) . Kampfer et al., (1996) , however, did not ®nd a correlation between the presence of p53 and the levels of Bcl-2 expression in leukemic cell lines. In the most recent study, Banker et al. (1998) examined the p53 mutation in t(8;21)-bearing cell lines as well as in primary AML cells and found that cell lines had mutation in p53 but primary cells did not. Based on these results, they speculated that p53 mutations may contribute to higher Bcl-2 expression levels in leukemia cell lines. Although further studies are required to unequivocally clarify the mechanisms by which Bcl-2 expression is modi®ed by AML1/ETO or p53 in primary leukemic cells, overall conclusion of Banker and others is entirely consistent with ours obtained in the current study.
Expression of AML1/ETO alone is not considered to be sucient to convert normal myeloid cells to leukemic cells, since some patients in remission have cells expressing AML1/ETO. Furthermore, transgenic mice containing tetracyclin-inducible AML1/ETO did not develop leukemia upon induction of the gene in the myeloid lineage (Don-Er Zhang, personal communication). The primary event induced by AML1/ETO might be upregulation of Bcl-2, even if over-expression of Bcl-2 is not sucient to induce leukemia. However, as summarized above, the phenotypes of 32Dcl3 cells over-expressing Bcl-2 and AML1/ETO are so dierent that this interpretation appears unlikely.
The chimeric protein, b/SMMHC, interacts with AML1 more eciently than the normal b subunit and sequesters AML1 to the cytoplasm. As a result of this interaction, the level of functional PEBP2 is presumed to be insucient in nuclei, resulting in deregulation of genes under the control of PEBP2 (Kanno et al., 1998) . In accordance with this observation, b/SMMHC severely represses promoter activities (Liu et al., 1994; Kanno et al., 1998) . It is interesting to note that ME-1 cells expressing b/SMMHC express Bcl-2 at levels even higher than those observed in Kasumi-1 and SKNO-1 cells. If the molecular mechanisms of upregulation of Bcl-2 by AML1/ETO and b/SMMHC are the same, we must consider the possibility that AML1/ETO stimulates the Bcl-2 promoter by derepressing transcription through the PEBP2 site. Detailed studies will be required to clarify this issue. Although AML1/ETO stimulates expression of Bcl-2 by acting directly on the regulatory region of the Bcl-2 gene, sustained expression of Bcl-2 in 32D-AML1/ETO appears to be due to a dierent mechanism as discussed below.
Over-expression of exogenous Bcl-2 did not block dierentiation of 32Dcl3 cells. However, continuously growing 32Dcl3 cells in the presence of G-CSF appeared to be prevented from downregulating Bcl-2 expression. As discussed above, the reason why 32Dcl3 cells expressing AML1/ETO were able to grow continuously in the presence of G-CSF was not because of AML1/ETO induced Bcl-2 expression. Rather, it seems possible that Bcl-2 expression is not inhibited in such cells even in the presence of G-CSF.
We reported earlier that Ear-2, a member of the orphan nuclear receptor family, blocked dierentiation of 32Dcl3 cells and that cells expressing Ear-2 continued to grow in the presence of G-CSF (Ahn et al., 1998) . Interestingly, we observed continuous expression of Bcl-2 in 32Dcl3 cells expressing Ear-2 in the presence of G-CSF (data not shown). Parental 32Dcl3 cells use G-CSF as a dierentiation factor but both AML1/ETO and Ear-2 are able to induce 32Dcl3 cells into using G-CSF as a growth factor. It would be physiologically meaningful for cells to continue to express Bcl-2 during growth and to downregulate Bcl-2 expression during dierentiation. Therefore, the cells expressing AML1/ETO may have acquired the ability to prevent downregulation of Bcl-2 in the presence of G-CSF by the mechanism which subverted the cells into interpreting G-CSF signals as those of a growth factor. From this point of view, the continuous expression of Bcl-2 in 32Dcl3 cells expressing AML1/ ETO could still be a consequence of the function of AML1/ETO, although the mechanism is completely dierent from that suggested by Klampfer et al. (1996) . How 32Dcl3 cells are transformed by AML1/ETO to read signals from G-CSF as those of a growth factor will be critically important for our understanding of the mechanism of leukemogenesis.
One obstacle to our hypothesis that a loss of AML1 function predisposes to leukemia is the observed AML1/ETO stimulation of Bcl-2 expression. The results shown in this paper suggest that this is not a serious obstacle. Stimulation of the M-CSF receptor by AML1/ETO needs to be examined in more detail.
Materials and methods
Cells and culture
Murine myelomonocytic cell line, WEHI-3B, (Warner et al., 1969) and human myeloid leukemia cell lines, Kasumi-1 (Asou et al., 1991) and SKNO-1 (Matozaki et al., 1995) harboring t(8;21), HL-60 (Collins et al., 1977; Rovera et al., 1979; Breitmann et al., 1980) , U937 (Sundstrom et al., 1976) , K562 (Lozzio et al., 1975) and ME-1 harboring inv(16) (Yanagisawa et al., 1991) were grown in RPMI1640 medium supplemented with 20% (Kasumi-1) or 10% (HL-60, SKNO-1, ME-1, U937, K562 and WEHI-3B) fetal bovine serum (culture medium, CM). A murine interleukin-3 (IL-3) dependent myeloid progenitor cell line derived from normal bone marrow long-term culture, 32Dcl3 (Valtieri et al., 1987) , was maintained in RPMI1640 containing 10% fetal bovine serum supplemented with 5% WEHI-3B culture supernatant as a source of IL-3 (IL-3 medium).
Plasmid constructions
To construct the mouse Bcl-2 expression plasmid, pEFBOSneoKR, the XhoI fragment containing the coding sequence for mouse Bcl-2 from pSKMBKR (obtained from M Tsujimoto of Osaka University) (Negrini et al., 1987) and pEF-BOSneo (Mizushima et al., 1990) digested with XbaI were blunt-ended by T4 DNA polymerase and ligated.
Establishment of 32Dcl3 stable transformants 32Dcl3 cells (5610 6 ) were washed three times in HeBS (HEPES-buered saline, pH 7.05) (Ausubel et al., 1987) and resuspended in 280 ml of HeBS. Twenty mg of pEFBOSneoKR or pEF-BOSneo in 20 ml of TE was mixed with the cells and transferred to cuvettes with a 0.2 cm gap (BioRad). Electroporation was performed using a Gene Pulser (Bio-Rad) at 270 V, 960 mF. Samples were transferred to the IL-3 medium and incubated. Forty-eight hours later, G418 (GIBCO) was added at a concentration of 0.6 mg/ml. Clones of stable transfectants were selected by limiting dilution. The Inability of Bcl-2 to block differentiation of 32Dcl3 H Kohzaki et al isolation of AML1/ETO stable transformants was described previously (Ahn et al., 1998) .
Induction of dierentiation
For the induction of granulocytic dierentiation, 32Dcl3 or its derivatives were washed twice with phosphate-buered saline (PBS) and cultured in the medium containing 500 U/ml of recombinant human granulocyte colony stimulating factor (rhG-CSF) (Kirin Beer, Japan). The medium was changed every 2 days with fresh G-CSF. For morphological examination, cells were washed with PBS twice and deposited onto glass slides by Cytospin and stained with May ± GruÈ nwald ± Giemsa for microscopic examination.
Cell survival assays
Cells in logarithmic growth phase were washed three times with fresh CM with no added cytokines and cultured in the same medium in triplicate at a cell density of 4610 5 cells/ml. The number of viable cells was determined by trypan blue staining (Rodel et al., 1996) .
Preparation of whole cell extracts and Western blotting
Cells (5610 5 ) were pelleted and suspended in 50 ml of SDS sample buer containing 62.2 mM Tris-HC1 (pH 6.8), 50 mM DTT, 2% sodium laurylsulfate (SDS), 10% glycerol, 0.1% bromphenolblue and 0.1% xylene cyanol, sonicated for 20 s and boiled for 5 min. Ten ml of each cell extract was subjected to 15% SDS-polyacrylamide gel electrophoresis (PAGE) and proteins were transferred to ImmobilonTM (MILLIPORE). Bcl-2 protein was detected by anti-Bcl-2 monoclonal antibody (Transduction Laboratory) and ECL immunodetection system (Amersham). Bcl-2 protein detected by Western blotting was quanti®ed with Quantity one (PDI, Inc.).
